|drug5||- Synthetic anti-malarial drugs Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.
Description: Percentage of patients with a significant stabilization of hemodynamics ("shock reversal"), defined as a significant reduction of the noradrenaline dose (≤ 0.05 µg/kg/min) while maintaining mean arterial pressure ≥ 65 mmHg for at least 24 hours compared to control groupMeasure: Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours Time: 24 hours
Description: Change in organ dysfunction based on "Sequential Organ Failure Assessment" (SOFA) Score The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure) The worst physiological variables were collected serially every 24 hours of a patient's ICU admission. The "worst" measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.Measure: Change in organ dysfunction Time: 10 days
Description: Improving lactate clearance by lowering serum lactate levelsMeasure: Lactate clearance Time: 10 days
Description: Time with need for renal replacement therapyMeasure: Renal replacement therapy Time: 10 days
Description: Time with Need for Extracorporeal Membrane OxygenationMeasure: Extracorporeal Membrane Oxygenation Time: 10 days
Description: ICU length of stayMeasure: ICU length of stay Time: 90 days
Description: Time on mechanical ventilationMeasure: Time on mechanical ventilation Time: 10 days
Description: Cumulative catecholamine doseMeasure: Cumulative catecholamine dose Time: 10 days
Description: Overall and ICU mortalityMeasure: Overall and ICU mortality Time: 90 days
Description: Change of plasma Interleukin-6 (IL6) levelMeasure: Change of plasma Interleukin-6 (IL6) level Time: 10 days
Description: Change of plasma Interleukin-10 (IL10) levelMeasure: Change of plasma Interleukin-10 (IL10) level Time: 10 days
Description: Change of plasma Procalcitonin (PCT) levelMeasure: Change of plasma Procalcitonin (PCT) level Time: 10 days
Description: Change of HLA-DR (Human Leukocyte Antigen - DR isotype) level of monocytesMeasure: Change of HLA-DR level Time: 10 days
Description: Change of TNF-alfa level (Tumor Necrosis Factor alpha) level after LPS (Lipopolysaccharides) stimulation as sign of monocytic immunocompetenceMeasure: Change of TNF alpha level after ex-vivo stimulation Time: 10 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports